Scarica l'app Stockscreener
24.50
3.64%
0.86
Dopo l'orario di chiusura:
24.30
-0.20
-0.82%
Precedente Chiudi:
$23.64
Aprire:
$24.08
Volume 24 ore:
3.96M
Relative Volume:
0.62
Capitalizzazione di mercato:
$12.24B
Reddito:
$4.89B
Utile/perdita netta:
$-242.00M
Rapporto P/E:
-50.10
EPS:
-0.489
Flusso di cassa netto:
$315.00M
1 W Prestazione:
+10.71%
1M Prestazione:
-5.15%
6M Prestazione:
-2.78%
1 anno Prestazione:
+39.84%
Intervallo 1D:
$24.00
$24.57
Intervallo di 1 settimana:
$22.17
$24.57
Portata 52W:
$17.11
$27.98
Elanco Animal Health Inc Stock (ELAN) Company Profile
Nome
Elanco Animal Health Inc
Settore
Telefono
877-352-6261
Indirizzo
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
24.50 | 11.81B | 4.89B | -242.00M | 315.00M | -0.489 |
TAK
Takeda Pharmaceutical Co Adr
|
18.34 | 57.64B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.47 | 42.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.87 | 42.75B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.68 | 30.56B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
529.14 | 22.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Citigroup | Buy |
| 2026-01-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-21 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Aggiornamento | Argus | Hold → Buy |
| 2025-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Iniziato | UBS | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Market Perform |
| 2024-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Aggiornamento | Stifel | Hold → Buy |
| 2023-12-19 | Iniziato | Jefferies | Buy |
| 2023-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-04-20 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Downgrade | Goldman | Buy → Sell |
| 2022-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-28 | Downgrade | Stifel | Buy → Hold |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-06-15 | Aggiornamento | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Iniziato | Stifel | Buy |
| 2021-03-22 | Downgrade | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Downgrade | Argus | Buy → Hold |
| 2020-11-09 | Downgrade | Barclays | Overweight → Underweight |
| 2020-08-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Ripresa | Credit Suisse | Neutral |
| 2020-08-04 | Ripresa | Goldman | Buy |
| 2020-07-27 | Downgrade | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Iniziato | Barclays | Overweight |
| 2019-08-26 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Neutral |
| 2019-03-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Iniziato | William Blair | Mkt Perform |
| 2019-01-23 | Iniziato | UBS | Sell |
| 2019-01-15 | Iniziato | Argus | Buy |
| 2018-10-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Elanco Animal Health Inc Borsa (ELAN) Ultime notizie
Attention investors: You may be eligible for a $15 million Elanco Animal Health SEC fair fund payment - Claim Depot
Elanco Animal Health (NYSE:ELAN): Is More Momentum Ahead? - Kalkine Media
Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC’s ‘Final Trades’ - benzinga.com
160,631 Shares in Elanco Animal Health Incorporated $ELAN Purchased by First National Bank of Omaha - MarketBeat
Shiv O'neill Purchases 3,998 Shares of Elanco Animal Health (NYSE:ELAN) Stock - MarketBeat
Elanco (NYSE: ELAN) legal chief buys 3,998 company shares - Stock Titan
FRAUD AND MANIPULATION—7th Cir.: Panel affirms dismissal of channel-stuffing allegations - VitalLaw.com
S&CO Inc. Buys Shares of 111,284 Elanco Animal Health Incorporated $ELAN - MarketBeat
7th Circ. Won't Revive Elanco Investors' Securities Fraud Suit - Law360
Is Elanco Animal Health Inc (ELAN) Overvalued After 5.2% Rally? - GuruFocus
Elanco Investors Fail to Revive Sales Misrepresentation Suit (2) - Bloomberg Law News
Elanco's CLiK Extra Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species - FinanzNachrichten.de
Elanco Animal Health (ELAN) Institutional Ownership 2026 $ELAN - MarketBeat
5 Must-Read Analyst Questions From Elanco’s Q2 Earnings Call - Yahoo Finance
Elanco Animal Health (NYSE:ELAN) Director Buys 5,000 Shares - MarketBeat
Elanco Animal Health (ELAN) director purchases 5,000 shares of stock - Stock Titan
Elanco rating upgraded by Fitch on deleveraging progress - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Elanco Animal Health expands US screwworm response - foxbusiness.com
Elanco (ELAN): Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform - Seeking Alpha
Elanco Animal Health Incorporated (ELAN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Elanco Animal Health (ELAN) Insider Buying: EVP and CFO Robert V - GuruFocus
Elanco receives FDA emergency authorization for screwworm spray - Investing.com
Elanco's CLiK(TM) Extra (Dicyclanil Topical Suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Speci - ACCESS Newswire
Insider Buying: Elanco Animal Health (NYSE:ELAN) CFO Buys $96,936.00 in Stock - marketbeat.com
Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Buys 10,000 Shares of Stock - MarketBeat
ELAN Stock Jumps As Earnings Beat Fuels Bullish Guidance - StocksToTrade
Elanco Animal Health (NYSE: ELAN) EVP granted new deferred stock units - Stock Titan
Elanco (ELAN) CFO boosts stake with 4,200-share buy and new Deferred Stock Units - Stock Titan
Elanco (ELAN) CEO Jeffrey Simmons receives new deferred stock unit grant - Stock Titan
Elanco Animal Health (NYSE: ELAN) director buys 10,000 shares at $23.69 - Stock Titan
Bank of America Corp DE Has $80.36 Million Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Does Elanco (ELAN) Have a Durable Edge in Animal Health After Its Screwworm EUA Win? - Yahoo! Finance Canada
Elanco Animal Health (ELAN) Following FDA Emergency Use Authorization Has Valuation Back In Focus - Yahoo Finance
INVESTOR ALERT AND NOTICE: Kaskela Law Firm Announces Investigati - The National Law Review
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Elanco Animal Health Q2 Earnings Call Highlights - MarketBeat
elanco animal health inc. Positive Earnings Pre-Announcements - RTTNews
ELAN Looks 42.8% Overvalued on GF Value™ - GuruFocus
Elanco Animal Health Inc (ELAN) Shares Fall 8.6% -- GF Value Says Still Overvalued - GuruFocus
Elanco Animal Health Incorporat (ELAN) Stock forecasts - Yahoo Finance UK
ELAN Looks 35.7% Overvalued on GF Value™ as Market Prices in Fut - GuruFocus
Elanco wound spray can help protect livestock from screwworm - stocktitan.net
Elanco Animal Health (NYSE:ELAN) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
Elanco Ends Lobbying Relationship With Stumptown Strategies - Legis1
Amundi Has $2.35 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
Cetera Investment Advisers Buys 65,526 Shares of Elanco Animal Health Incorporated $ELAN - marketbeat.com
UBS Adjusts Price Target on Elanco Animal Health to $33 From $31, Maintains Buy Rating - Moomoo
Elanco Animal Health Inc (ELAN) Shares Fall 7.7% -- What GF Scor - GuruFocus
Elanco CEO on Boosted Forecast, Surge in Tick Bites - Yahoo Finance
Elanco raises 2026 outlook after strong second-quarter results - Feed Strategy
Elanco Animal Health Inc Azioni (ELAN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.33%
0.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):